For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .
Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study.
PURPOSE To determine the efficacy and safety of oral sildenafil citrate in the treatment of erectile dysfunction ( ED ) in diabetic men . MATERIAL S AND METHODS In a r and omized , double-blind , placebo-controlled , and fixed-dose study , a total of 282 men ( mean age , 46.4 years ) with ED ( mean duration , 3.6 years ) and diabetes ( mean duration , 11 years ) were r and omly assigned to receive 100 mg sildenafil ( n=144 ) or placebo ( n=138 ) approximately 1 h before planned sexual activity , but not more than once daily , for 16 weeks . The efficacy of two treatments was assessed using responses to the International Index of Erectile Function ( IIEF ) question naire . RESULTS Two hundred sixty-two ( 93 % ) of men completed the study ( 134/144 in the sildenafil group , 128/138 in the placebo group ) . Positive clinical results were obtained in 68 ( 51 % ) of 134 patients in the sildenafil group compared with 14 ( 11 % ) of 128 patients in the placebo group ( P<.003 ) . Fifty-nine percent of the patients reported at least one successful attempt at sexual intercourse in the sildenafil group as compared with 21 % successful attempts for the placebo group ( P<.002 ) . Drug-related adverse effects occurred in 32 ( 22 % ) of 144 patients taking sildenafil and 4 ( 3 % ) of 138 patients receiving placebo . The most common adverse events were headache ( 20 % sildenafil , 2 % placebo ) , flushing ( 19 % sildenafil , 0 % placebo ) , dyspnea ( 9 % sildenafil , 2 % placebo ) , rhinitis ( 6 % sildenafil , 0 % placebo ) , and cardiovascular effects ( 7 % sildenafil , 0 % placebo ) . Of patients taking sildenafil , four ( 2.7 % ) developed new chest pains , with documented myocardial infa rct ion in two . CONCLUSION Oral sildenafil is a moderately effective treatment for ED in men with diabetes . The response rate was lower and cardiovascular events were higher than previously reported in nondiabetic patients
For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .